Table 3.

Favorable response (complete plus partial) by patient subgroup (N = 101)

Variable	Favorable response % (n/N) [95%CI]
Overall	56.4 (57/101) [46.7; 66.1]
Probable aspergillosis	56.3 (40/71) [44.0; 68.1]
Proven aspergillosis	56.7 (17/30) [37.4; 74.5]
Combination therapy	56.3 (9/16) [29.9; 80.2]
First line	60.0 (3/5) [14.6; 94.7]
Second Line	54.6 (6/11) [23.4; 83.3]
Monotherapy	56.5 (48/85) [45.3; 67.2]
First line	60.0 (9/15) [32.3; 83.7]
Second Line	55.7 (39/70) [43.3; 67.6]
First-line therapy	60.0 (12/20) [36.1; 80.9]
Salvage therapy	55.6 (45/81) [44.1; 66.6]
Culture examination performed	62.3 (38/61) [50.1; 74.5]
Positive	55.6 (15/27) [36.9; 76.6]
Negative	67.6 (23/34) [49.5; 82.6]
Neutropenic status at start of caspofungin therapy
ANC < 500 cells/μL	52.5 (31/59) [39.1; 65.7]
ANC > = 500 cells/μL	61.9 (26/42) [45.6; 76.4]
Risk factors
Active malignancy	51.9 (41/79) [40.4; 63.3]
AIDS/HIV infection	66.7 (2/3) [9.4; 99.2]
Bone marrow/stem cell transplantation	53.6 (15/28) [33.9; 72.5]
• Autologous HSCT	40.0 (2/5) [5.3; 85.3]
• Allogeneic HSCT	56.5 (13/23) [34.5; 76.8]
Diabetes mellitus	57.1 (8/14) [28.9; 82.3]
Immunosuppressive medication	60.8 (45/74) [48.8; 72.0]
Neutropenia at the time of hospitalization	53.0 (35/66) [40.3; 65.4]
Prior fungal colonization	61.1 (11/18) [35.7; 82.7]
Organ transplantation	75.0 (6/8) [34.9; 96.8]

Response evaluated in N = 101 patients.